Cystic hygroma (CH) is a lymphatic malformation occurring different parts of fetal body, typically in the region of the fetal neck and axillary, abdominal wall, mediastinal, inguinal and retroperitoneal areas. CH has been associated with fetal aneuploidy, hydrops fetalis, structural malformations and intrauterine fetal death.
Introduction
Cystic hygroma (CH) is a lymphatic malformation occurring in different parts of fetal body, typically in the region of the fetal neck and axillary, abdominal wall, mediastinal, inguinal and retroperitoneal areas. 1,2 CH may result from a complete or incomplete obstruction in the lymphatics that prevents communication with the venous system and causes cysts. 3 The hygroma describes an endotheliallined mass consisting of small to-mediumsized lumina containing lymphatic fluid, together with a mixture of loose collagen tissue, adipose tissue and, occasionally, vascular tissue. The cysts may be unilocular, but more often the structure contains multiple cysts infiltrating the surrounding structures and distorting the local anatomy. 4 The lack of lymphatic drainage leads to an increased volume of flow in the venous system, resulting in large veins. 5 The septated CH may result from a complete obstruction in the lymphatic sacs that prevents communication with the venous system and causes lymph fluid to accumulate and dissect into tissues, thus creating large multilocular cysts. Nonseptated CH may result from a temporary accumulation of lymph fluid due to incomplete obstructions of lymphatic drai nage. 6, 7 Increased lymphatic pressure may sometimes overcome the incomplete obstructions, thus explaining the higher spontaneous resolution rate reported with nonseptated CH. [6] [7] [8] CH has been associated with fetal aneuploidy, hydrops fetalis, structural malformations and intrauterin fetal death. [9] [10] [11] In particular they may be associated with Turner syndrome, Noonan syndrome, Trisomies, cardiac anomalies and fetal hydrops. 12 Two distinct categories of fetal CH have been described: those diagnosed in later pregnancy, which tend to be isolated lymphangiomas, and those diagnosed in early pregnancy, which are commonly associated with other malformations. 13, 14 Retrospective case series describing the prenatal diagnosis of this condition suggest that those diagnosed early in pregnancy are associated with a poor prognosis. 8, 13, 14 When CH appears septated, the prognosis is considered even worse than the nonseptated form. 8, 15 Axillary CH was rarely reported and determined often in midgestation. 16, 17 The purpose of this study was to evaluate karyotypic, ultrasonographic and prognostic factors of CH diagnosed during pregnancy and to describe an axillary localized CH case.
Case Report
A 24-years-old woman, gravida 1, para 1, admitted to our antenatal clinic for gestational follow-up. The patient didn't take any antenatal care until admission to our clinic. Her socio economic status was not good. The woman didn't use folic acid drugs neither before the pregnancy nor during the pregnancy. She was nonsmoker and nondrinker. There was no systemic illness and operation in her past medical history. Patient's vital signs, routine blood and urine tests were found normal. Ultrasonographic examination determined 28 weeks of gestation, singleton, alive fetus who had a mass derived from the right axillary region which was extending to the anterior and posterior thoracic wall with fluid-filled cavities about 12 cm in size (Figure 1 ). Fetal biometry was appropriate for gestational age, placenta and amniotic fluid were normal. No other fetal anomalies were identified. Color velocity imaging demonstrated no flow through the mass. The diagnosis of axillothoracic CH was corrected by magnetic resonance imaging (MRI) examination (Figure 2 ). There was no evidence of intrathorasic or intraabdominal extension of mass. Fetal thorax and abdomen were found normal in MRI examination. The cordocentesis was performed after the patient's informed consent was taken. Karyotype examination was normal 46 XY. Patient was followed up as outpatient by the high risk pregnancy department. The patient admitted to antenatal clinic 3 weeks later again because of the lack of fetal movements. In ultrasonographic evaluation, fetal demise was found. The mass was seen as the same size, and there wasn't any sign of hydrops fetalis , the amniotic fluid was found normal. The patient delivered vaginally after labor induction with oxytocin infusion. Multiple cord entanglements were found around fetal neck. During the delivery, fetal or cystic damage was not happened. In postnatal examination a multicystic, transluminating mass was seen which measured 15 cm was in maximum diameter. The mass was extending from axilla to anterior and posterior thoracic wall. There was no fetal anomaly in fetal macroscopic examination except axillothorasic cystic mass and there was no apparent invasion of the mass into chest cavity and no parenchymal lung disease. As a result of the fetal autopsy and pathological findings, it was diagnosed as CH. Histological examination demonstrated cystic lymphangioma with dilated communicating lymphatic vessels lined by normal epithelium and cystic areas with rare aggregates of lymphocytes ( Figure 3 ). Additional fetal anomaly wasn't detected.
Discussion
Fetal CH is a congenital malformation in which distended fluid-filled spaces develop, typically in the region of the fetal neck. Cystic hygromas are slow-growing benign tumours resulting from a developmental anomaly of the lymphatic system. 18 The lymphatic system begins to develop in 6 weeks, and then combines with venous system. The inability of combination between venous system and lymphatic system results in CH. 18, 19 CH has been associated with fetal aneuploidy, hydrops fetalis, structural malformations and intrauterin fetal death. [9] [10] [11] It is reported to occur between 1 in 6000 and 1 in 16,000 live births but it is estimated to be much more than this proportion as we take into account the abortions (1/875). 18, 19 CH can occur anywhere in the body, but 75% involve the posterior neck, 20% the axilla and 1% the mediastinum, groin and retroperitoneum. 19, 20 In particular they may be associated with Turner syndrome, Noonan syndrome, Trisomies, cardiac anomalies, fetal hydrops. 12 If this inability is severe, the progressive peripheral lymph edema and hydrops develops and results in early fetal loss. 19 Two distinct categories of fetal CH have been described: those diagnosed in later pregnancy, which tend to be isolated lymphangiomas, and those diagnosed in early pregnancy, which are commonly associated with other malformations. 13, 14 Retro spective case series describing the prenatal diagnosis of this condition suggest that those diagnosed early in pregnancy are associated with a poor prognosis. 8, 13, 14 When CH appears septated, the prognosis is considered even worse than the nonseptated form. 8, 15 The CH in later gestation, which likely represents a lymphangioma that is not associated with either aneuploidy or other fetal malformations, and can be expected to yield a good prognosis.
13,14 CH incidence is equal in both sexes, but the inguinal CH is 5 times more common in men. 21 A total of 38,167 patients were enrolled at 15 study centers, and a total of 134 cases of CH were diagnosed in this population. Chromosomal abnormality was diagnosed in 67 of 132 cases (51%) of CH. 22 tion was cardiac abnormalities (in 7 cases, 20%) in nonseptated CH cases and nonimmune hydrops (in 12 cases, 54.5%) in septated CH cases. 24 Sixty-four cases of CH in 8524 patients were detected (0.75%). Thirty-nine (60.9%) were of non-septated and 25 (39.1%) were of septated CH. Chromosomal abnormalities were present in 25 (39.1%). The most common abnormality in non-septated CH was trisomy 21 (27.8%), and that in septated CH was Turner syndrome (23.8%). Nine of the infants were live-born and were subsequently followed up but, two had cardiac pathology and died after cardiac operation, two others were diagnosed with axillary CH, had an excellent prognosis. Only three cases had, at birth and in the follow-up period, no complications.It was indicated that the CH is highly correlated with adverse perinatal outcome. 25 Previously, a large multicenter study reported that there were 134 cases of CH among 38,167 screened patients (1 in 285). Chromosomal abnormalities were diagnosed in 67 (51%), including 25 trisomy-21, 19 Turner syndrome, 13 trisomy-18, and 10 others. Major structural fetal malformations (primarily cardiac and skeletal) were diagnosed in 22 of the remaining 65 cases (34%). Overall, survival with normal pediatric outcome was confirmed in 17% of cases (22 of 132). The CH has 5-fold, 12-fold, and 6-fold increased risk of aneuploidy, cardiac malformation, and perinatal death, respectively. 26 Chromosomal abnormalities were found 52.7% (38/72) in 72 fetuses who had detected CH at first trimester screening and, including 14 cases (36.8%) of Down syndrome. A total of 34 chromosomally normal pregnancies ended with 18 live births (52.9%), with no visible serious structural abnormalities. The 18 live-born infants were followed up for 17-98 months. Sixteen infants developed normally, while 1 developed Noonan's syndrome and 1 had a urinary tract abnormality. These data suggest that the prognosis of fetal CH detected during the first trimester is poor. 27 Axillary CH is rarely reported and determined often by sonographically in midgestation. 16, 17 Axillothoracic CH may be diagnosed during routine antenatal ultrasound follow-up. These are the masses simple or multicystic structured, hypoechogenic, with thin septat, and they may contain solid components. 28, 29 Generally, the vascular flow isn't seen in the Doppler ultrasound examination. MRI is important in determining the characteristics of the tissue and tumor extent. 30 Axillary lymphangiomas account for approximately 10% of all lymphangiomas. Very few have been reported as diagnosed prenatally. 6 A few cases have been reported of shoulder dystocia caused by axillary lymphangioma diagnosed after delivery. 7 McCoy et al. reported, a child with bilateral axillary CH that were prenatally diagnosed at 18th week of gestation. 31 Traditionally, ultrasonography has been used as the primary screening method for prenatal diagnosis, especially in cervical lesions. CT is avoided because of issues relating to radiation exposure to mother and foetus. MRI may play a role in prenatal imaging, as amongst other things it provides early comprehensive information about both the anatomy and the extension of the tumour. 32 Obstetric prognosis in CH cases depends on the volume and localization of the mass. Fetal prognosis is determined by the degree of chromosomal anomalies and hydrops. 33 With serial ultrasound follow-up, the size of the mass is followed and for the masses that may develop dystocia so section is recommended. In isolated small masses, the standard obstetric treatment is recommended. In larger masses that may prevent the birth, intrauterine cyst aspiration may be carried out and this process also can be carried out for intrauterine diagnosis. 28 Generally, CH has no risk of recurrence in subsequent pregnancies. But recurrent familial CH cases have been reported in the literature. 34 In prenatal differential diagnosis of axillothoracic CH, simple cysts, hemangiomas, bran chial cleft cysts, hemongiolymphangiomas, lymphocele, teratomas, hemongioendotheliomas, ectopia cortis, amniotic band syndrome, Klippel-Trauray syndrome should be considered. 35 These tumors do not show spontaneous recovery after childbirth, they are treated surgically with excision. Infiltrative and extensive masses are difficult to be extracted surgically. If total surgical excision isn't carried out, the recurrence may be seen. Other treatment options include injections of the sclerosing agent, CO 2 laser therapy and radiotherapy. 12, 35 When the cyst is aspirated with an injector, it may lead to the rapid fluid accumulation and it isn't suggested as it may cause infection. 12 For the treatment of CH, the new modality is the use of sclerosing agents. 36 For the first time in 1986, by Ogita et al. proposed treatment of intralesional injection of OK-432. 37 OK432 is a sclerosing agents obtained from derivative of low virulence Streptococcus pyogenes.
38 OK432 activates white blood cells; increases cytokines (such as TNF) improves endothelial permeability and improves the lymphatic drainage from the cystic area. 39 OK423 has been accepted as safe and effective alternative treatment. 39 It may be used as a primary treatment and after recurrent CH or partial surgical treatment. The success of the treatment of multicystic CH is low but it is better in simple cysts. It has no effect on post-surgical treatment after OK432 treatment. As it doesn't cause the formation of fibrosis in surgical excision area, it does not affect the surgery after the injection. 35 Recently, intrauterine OK432 treatments have been reported. 36 The fetal CH carries high risk of aneuploidy and fetal malformations. Patients that have been diagnosed with CH in antenatal followups should be assessed in terms of other anomalies, fetal karyotyping should be done and the patient should be monitored for fetal hydrops. The cyst size and structure, septat or nonseptat, localization and invasion of cyst are important prognostic factors. The axillary localization and spontaneous resolution of septa are good prognostic factors. The birth should be planned in a multidisciplinary hospital and as neonatal resuscitation could be needed, pediatricians should be consulted.
